TCLIF (Theraclion) Cyclically Adjusted PS Ratio: (As of Aug. 01, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TCLIF Theraclion TCLIF
27 GF Score
Price $0.53
GF Value $0.23
! 7 Warning Signs
View Full Analysis

What is Theraclion Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Theraclion  (OTCPK:TCLIF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Theraclion Cyclically Adjusted PS Ratio Related Terms


Theraclion Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Theraclion's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theraclion Cyclically Adjusted PS Ratio Chart

Theraclion Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.48 4.60 1.87 1.79 4.14

Theraclion Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.87 0.00 1.79 0.00 4.14

TCLIF vs ABT, SYK, MDT: Cyclically Adjusted PS Ratio Comparison

For the Medical Devices subindustry, Theraclion's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theraclion Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Theraclion's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Theraclion's Cyclically Adjusted PS Ratio falls into.


TCLIF
27GF Score
Theraclion TCLIF
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Theraclion Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Theraclion's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec25 is calculated as:

For example, Theraclion's adjusted Revenue per Share data for the fiscal year that ended in Dec25 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec25 (Change)*Current CPI (Dec25)
=0.023/120.9000*120.9000
=0.023

Current CPI (Dec25) = 120.9000.

Theraclion Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201612 0.299 100.650 0.359
201712 0.377 101.850 0.448
201812 0.255 103.470 0.298
201912 0.199 104.980 0.229
202012 0.055 104.960 0.063
202112 0.072 107.850 0.081
202212 0.040 114.160 0.042
202312 0.043 118.390 0.044
202412 0.018 119.950 0.018
202512 0.023 120.900 0.023

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Theraclion (TCLIF) Overvalued in 2026?

Based on GuruFocus' analysis, Theraclion stock appears to be overvalued. The current stock price of $0.53 is trading 131.3% above its estimated GF Value™ of $0.23.

Key valuation signals for TCLIF:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: $0.23 vs. price of $0.53 (131.3% above fair value)
  • GF Score™: 27/100 with 7 warning signs

No single metric tells the full story. See the TCLIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Theraclion Business Description

Other Exchanges ALTHE:France941:Germany
Address 244 Avenue Pierre Brossolette, Immeuble Le Vaillant, Malakoff, Paris, FRA, 92240
Theraclion specializes in developing, manufacturing, and marketing echotherapy equipment, associating therapy with focused ultrasound (HIFU) and monitoring by ultrasound. The company provides Echopulse, a device for non-invasive and outpatient treatment of mammary fibroadenoma and thyroid nodules. Its products include Sonovein, Echopulse, and Epack.
27GF Score

Get the complete analysis for TCLIF

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.53
Price
$0.23
GF Value